It is noted that for the appearance of immunity, one vaccination will be enough, not two.
The US Food and Drug Administration (FDA) approved an appeal by Janssen, owned by the US Corporation Johnson & Johnson, to register its vaccine against the new coronavirus under an accelerated procedure in emergency circumstances. This is stated in a statement issued by this regulatory body under the US Department of Health and Human Services.
“Today, the FDA issued emergency authorization for the use of a third vaccine against [the disease] COVID-19 caused by [the virus] SARS-CoV-2. The emergency use permit allows the use of Janssen in the United States when vaccinating people aged 18 years and older, ”the report says.
“The approval of this vaccine expands the availability of drugs that are the best way to prevent the coronavirus, and they will help us in the fight against this pandemic, which has already claimed the lives of more than half a million people in the United States,” said Janet Woodcock, acting director of the FDA.
The drug from Janssen has already become the third coronavirus vaccine approved for use in the United States. At the same time, one vaccination will be enough for the appearance of immunity, not two, as in the case of drugs from Moderna and Pfizer, and BioNTech.
Earlier, the FDA informed that the results of the third phase of trials of the vaccine from Johnson & Johnson had been proven to be effective and safe. At the end of last week, the corporation posted on its website that it had submitted an application to the World Health Organization for approval for the emergency use of the vaccine of its Janssen division. Johnson & Johnson has submitted a package of documents to the organization, including preliminary assessments of the safety and effectiveness of the drug based on data obtained during the third stage of clinical trials. According to the corporation, the vaccine demonstrated the effectiveness of up to 85% during this phase.